Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

ClinicalTrials.gov ID: NCT00860574

Public ClinicalTrials.gov record NCT00860574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL)

Study identification

NCT ID: NCT00860574
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Fred Hutchinson Cancer Center; Other
Enrollment: 96 participants

Conditions and interventions

Conditions

Interventions

allogeneic bone marrow transplantation Procedure
allogeneic hematopoietic stem cell transplantation Procedure
fludarabine phosphate Drug
methotrexate Drug
peripheral blood stem cell transplantation Procedure
tacrolimus Drug
total-body irradiation Radiation
treosulfan Drug

Procedure · Drug · Radiation

Eligibility (public fields only)

Age range: Up to 60 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2009
Primary completion: Jan 31, 2013
Completion: Not listed
Last update posted: Jun 21, 2021

Started 2009

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
University of Colorado	Denver	Colorado	80217-3364	—
Oregon Health and Science University	Portland	Oregon	97239	—
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00860574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 21, 2021 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00860574 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →